Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23387619 | 0.89 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1CYP2C9TAS2R14 | |
| SCHEMBL23387620 | 0.89 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1CYP2C9TAS2R14 | |
| SCHEMBL29180240 | 0.88 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1CYP2C9TAS2R14 | |
| SCHEMBL26655167 | 0.88 | CYP2D6 (0.45) | ALDH1A1KMT2AMEN1CYP2C9TSHR | |
| SCHEMBL7166740 | 0.88 | CYP2D6 (0.45) | ALDH1A1KMT2AMEN1CYP2C9TSHR | |
| SCHEMBL26655196 | 0.88 | CYP2D6 (0.45) | ALDH1A1KMT2AMEN1CYP2C9TSHR | |
| SCHEMBL7032005 | 0.88 | CYP2D6 (0.45) | ALDH1A1KMT2AMEN1CYP2C9TSHR | |
| SCHEMBL8907892 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1CYP2C9TAS2R14 | |
| SCHEMBL8899789 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1CYP2C9TAS2R14 | |
| SCHEMBL17815986 | 0.87 | ALDH1A1 (0.49) | ALDH1A1KMT2AMEN1CYP2C9TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024078581-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND USES THEREOF | APPICINE THERAPEUTICS (HK) LIMITED (CN) | 2024-04-18 | — | — | WO | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| EP-3609888-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018170182-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | ALDH1A1 1615/4885KMT2A 3153/4885MEN1 4390/4885 |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | ALDH1A1 2205/4885KMT2A 4719/4885MEN1 2725/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | ALDH1A1 1584/4885KMT2A 3232/4885MEN1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.